CDTX — Cidara Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $272.14m
- $82.89m
- $1.28m
Annual income statement for Cidara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.1 | 49.6 | 64.4 | 23.3 | 1.27 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 64.4 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 83.9 | 91.8 | 98 | 50.3 | 177 |
| Operating Profit | -71.8 | -42.3 | -33.5 | -27.1 | -176 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -72.1 | -42.5 | -33.3 | -25.1 | -170 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -72.1 | -42.5 | -33.6 | -25.1 | -170 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -72.1 | -42.5 | -33.6 | -22.9 | -170 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -74.9 | -42.5 | -33.6 | -22.9 | -170 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -36 | -16.2 | -9.61 | -5.74 | -13.5 |